December, 2021

article thumbnail

Digital health: the new normal?

pharmaphorum

Personalised and tailored healthcare that utilises patient’s data is rapidly becoming a reality. Ben Hargreaves looks at the concrete steps already being taken by companies in the area. Amongst the many ways in which the pandemic has changed the way in which we live, one of the most common experiences for most people was to revise what it means to have a face-to-face meeting.

145
145
article thumbnail

New inhaled SARS-CoV-2 antibody treatment set to enter clinical trials

Outsourcing Pharma

Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.

142
142
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Judge Overturns Purdue Pharma’s Opioids Settlement

NY Times

The ruling said the company’s owners, members of the Sackler family, could not receive protection from civil lawsuits in return for a $4.5 billion contribution.

145
145
article thumbnail

Cancer clinical trial recruitment drops by 60% during pandemic

Pharma Times

In a new report from The Institute of Cancer Research (ICR), data from cancer trials alongside assessments from clinicians and patients aims to provide guidance on how to improve services

127
127
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

2022 Predictions From the Front-Lines of Pharma Digital Advertising

Pharma Marketing Network

The pharma industry has been slower to embrace digital technologies than other less-regulated sectors but the COVID-19 pandemic has greatly changed this long-standing mindset. In 2020 and 2021, we saw pharma forced to become more flexible and open-minded than ever before. In this article, R.J. Lewis, Founder & CEO of eHealthcare Solutions and Tap Native, offers his top ten predictions for what’s ahead for pharma in 2022.

article thumbnail

Which pharmaceutical companies have the most drug patents in Czech Republic?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Czech Republic. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical companies have the most drug patents in Czech Republic? appeared first on DrugPatentWatch - Make Better Decisions.

More Trending

article thumbnail

Pfizer buys immuno-inflammatory firm Arena Pharmaceuticals for $6.7b

Outsourcing Pharma

The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.

article thumbnail

Will High Vaccination Rates Help Spain Weather Omicron?

NY Times

Spain surpassed others in Europe by avoiding politicized debate about Covid shots. Citizens also largely heeded the health guidance from their leaders.

Vaccines 140
article thumbnail

Possible identification of blood clot trigger for AstraZeneca COVID-19 vaccine

Pharma Times

Researchers have identified in those patients experiencing blood clots after vaccination a subsequent condition referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT).

Vaccines 125
article thumbnail

Getting Creative with Sustainability | How Pharma Engages

Pharma Marketing Network

Big pharma has compelling reasons to change the way business gets done. The wave of interest in sustainability follows the value chain from top-tier pharmaceutical companies to their suppliers of every size. Leaders are hard at work focusing their efforts on how to use sustainability as a platform for innovation. Step one is to assess your corporate social responsibility (CSR) policies and ensure actions are integrated across the organization.

article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Which pharmaceutical companies have the most drug patents in Brazil?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Brazil. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Brazil? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Digital health firm Pear goes public, raising $175 million

pharmaphorum

Pear Therapeutics has completed its merger with blank cheque company Thimble Point Acquisition Corp, claiming a Nasdaq listing and raising $175 million in gross proceeds for the digital health specialist. Pear will make its debut on the exchange today after combining with Thimble Point – a special purpose acquisition company (SPAC) – in a deal that sidestepped the conventional initial public offering (IPO) route and has propelled its valuation to around $1.6 billion.

133
133
article thumbnail

Insilico Medicine launches trial for AI-discovered drug

Outsourcing Pharma

The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.

141
141
article thumbnail

Firms Push for Over-the-Counter Access to Birth-Control Pills

NY Times

Two drugmakers have been mired for years in the pre-application phase of getting F.D.A. approval for over-the-counter use.

145
145
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Oxford and AstraZeneca aim to produce Omicron-targeted version of vaccine

Pharma Times

Calls for booster vaccinations in order to combat the rising cases brought about by winter and the recent Omicron variant have intensified, in the midst of record case rates.

Vaccines 121
article thumbnail

Watch: DHC Roundtable Discussion

Pharma Marketing Network

R.J. Lewis, Founder and CEO of eHealthcare Solutions and Tap Native and the Chief Collaborator at Pharma Marketing Network, moderated a deep dive discussion on the topic of physician-level data (PLD) with a focus around drivers for the tool, its usage, and successes learnings about its function in pharma, and the where it’s heading. Guests of the panel included experts from GSK, Ispen, BioPharm Communications, and CMI, who all spoke to the importance of incorporating and leveraging PLD ins

article thumbnail

Why GoodRx—Not Amazon—May Be the True PBM Disrupter (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from August 2021. The generic prescription market is being disrupted—but not by the big, bad spaceman from Seattle. Instead, consider how GoodRx is affecting patients, payers, and PBMs.

88
article thumbnail

UCB chases after Argenx with FcRN drug for myasthenia gravis

pharmaphorum

UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor (FcRn) antibody rozanolixizumab for autoimmune disease generalised myasthenia gravis (gMG), setting up regulatory filings next year. The MycarinG study met its primary endpoint, demonstrating a “statistically significant and clinically meaningful” improvement from baseline in the myasthenia gravis-activities of daily living (MG-ADL) score, said the Belgian drugmaker.

130
130
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Is artificial intelligence the best tool for drug discovery?

Outsourcing Pharma

According to a leader from Cytoreason, AI isnât necessarily the best or only tool suited to discover new and novel therapiesâit might take a human touch.

145
145
article thumbnail

Merck’s Covid Pill Might Pose Risks for Pregnant Women

NY Times

Some laboratory studies suggest that molnupiravir can insert errors in DNA, which could in theory harm a developing fetus, sperm cells or children.

129
129
article thumbnail

Cancer researchers across the UK partner in new trial to find drugs for rare cancers

Pharma Times

The DETERMINE trial aims to discover whether existing ‘licensed’ drugs could also benefit patients with rare cancer types that the drug is not currently licensed for.

118
118
article thumbnail

Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization?

Drug Patent Watch

This chart shows the drugs with the most patents in Eurasian Patent Organization. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization? appeared first on DrugPatentWatch - Make Better Decisions.

91
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

PBMs and Drug Spending in 2020: Data from CVS Health (sort of), Express Scripts, Navitus, and WellDyne (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from July 2021. Since 2012, Drug Channels has examined commercial drug spending using the annual trend reports published by the largest PBMs. This year, we review 2020 data on commercial plan sponsor clients of CVS Health and Express Scripts along with two smaller PBMs—Navitus and WellDyne.

article thumbnail

J&J goes after another FDA approval for a cancer bispecific

pharmaphorum

Johnson & Johnson’s much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and the drugmaker has now filed for FDA approval of a second candidate. The latest to reach the regulatory stage is teclistamab, one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J’s Janssen division stemming from its longstanding and fertile collaboration with Danish biotech Genmab.

article thumbnail

Michael J. Fox Foundation significantly expands Parkinson’s study

Outsourcing Pharma

The Parkinsonâs Progression Markers Initiative, built using Evidation Healthâs research platform, aims to triple enrollment and recruit online participants.

126
126
article thumbnail

Can Eye Drops Replace Reading Glasses?

NY Times

Vuity, a once-a-day treatment that can help users see up close without affecting their long-range vision, went on the market Thursday after being approved by the F.D.A. in October.

105
105
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Five-drug combination for ultra-high-risk bone marrow cancer identified

Pharma Times

A team at The Institute of Cancer Research (ICR), London and the Clinical Trials Research Unit (CTRU) at the University of Leeds adopted a new high-speed trial methodology.

112
112
article thumbnail

Which pharmaceutical drugs have the most drug patents in Norway?

Drug Patent Watch

This chart shows the drugs with the most patents in Norway. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Norway? appeared first on DrugPatentWatch - Make Better Decisions.

90
article thumbnail

Drug Channels News Roundup, December 2021: CAR-T Profits, UM Boom, Health Plans vs. Experts, Confused Physicians, and Health Insurance Explained

Drug Channels

Happy New Year, everyone! We made it through a challenging 2021. Ring in 2022 with these noisemakers from the Drug Channels party bag: Hospitals earn incredible markups on CAR-T therapies Utilization management booms Health plans often ignore clinical guidelines Benefit designs flummox physicians Plus: an awesomely concise summary of U.S. health insurance.

article thumbnail

AZ’s antibody first to be cleared by FDA for COVID prevention

pharmaphorum

AstraZeneca’s antibody cocktail for COVID-19, now called Evushield, has become the first drug in the class to be authorised for prevention of infection by the US FDA. The long-acting antibody combination, formerly known as AZD7442 (tixagevimab and cilgavimab) has been cleared for pre-exposure prophylaxis (PrEP) of COVID-19 in adults and adolescents aged 12 and older who weigh at least 40kg and have compromised immunity.

article thumbnail

Bias in artificial intelligence impacts drug development: AiCure

Outsourcing Pharma

According to an expert from the clinical insights company, prejudice in AI can impact patient outcomes as well as the ability to develop effective treatments.